Abstract 275P
Background
In 2022, the U.S. Food and Drug Administration (FDA) approved Lutetium-177 Prostate-specific membrane antigen (Lu-177 PSMA). This approval was based on the VISION trial, in which Lu-177 PSMA demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to standard therapy alone. PSMA is more strongly expressed in prostate cancer than in benign prostatic hyperplasia and correlates with Gleason Score and cancer grade. PSMA is involved in tumor growth by activating IP3K-AKT-mTOR signaling through folate metabolism. PSMA expression is suppressed by androgen receptor (AR) bound complexes with testosterone and promoted by unbound AR. In other words, inhibition of AR signaling enhances PSMA expression. These findings suggest that PSMA is involved in the mechanism of resistance to treatment in castration resistant prostate cancer (CRPC). Our previous study also showed that CRPC patients with PSMA expression in the blood circulating tumor cells (CTCs) have a shorter PFS. In this study, we aimed to determine the association between PSMA expression in CTCs and OS after the initiation of taxane-based chemotherapies in metastatic CRPC.
Methods
Forty-eight patients with metastatic CRPC treated with docetaxel followed by cabazitaxel were included in the study. PSMA expression in CTCs was analyzed over time, and the association between PSMA expression and OS was analyzed.
Results
Twenty-seven patients were positive for PSMA expression, and 21 patients were negative for PSMA expression in CTC. The analysis comparing patient backgrounds showed no significant differences with respect to Gleason Score, number of docetaxel treatments, prior ARATs administration, or metastatic site. On the other hand, patients with positive PSMA showed a longer time to acquire castration resistance. The log-rank test result showed shorter OS after initiation of docetaxel treatment in patients with positive PSMA than in those with negative PSMA (median survival at observation, PSMA-positive group: 618 days; PSMA-negative group: 1187 days; P=0.05).
Conclusions
The expression of PSMA in CTCs was associated with OS after initiation of taxane-based chemotherapy in metastatic CRPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract